BOSTON - Praxis Precision Medicines, Inc. (NASDAQ:PRAX) announced Tuesday it will immediately convert its EMBRAVE3 registrational study for elsunersen in SCN2A developmental and epileptic ...
Praxis Precision Medicines is converting its EMBRAVE3 study of elsunersen for children suffering from a developmental disease into a single-arm study after meeting with the Food and Drug ...
Praxis Precision Medicines, Inc. (PRAX) stock is soaring in trading today, up 35% at time of writing, with shares reaching a value of $260, their highest value since the beginning of 2022. Current ...
Investing.com -- Praxis Precision Medicines (NASDAQ:PRAX) stock surged 25% after the company announced its EMBOLD study evaluating relutrigine was stopped early due to positive efficacy results. The ...
BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA path BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage ...
As a college student, studying can be difficult and lonely. ChatGPT has become my go-to study buddy.
For me, studying in college is an overwhelming and isolating experience. I started using ChatGPT's voice feature to upload my study guides and talk through the topics. The AI helped me feel less alone ...
Praxis Precision Medicines, Inc. - GlobeNewswire - Mon Aug 25, 3:01PM CDT BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical ...
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results